

Eisai to divest rights for Merislon and Myonal in Japan to Kaken Pharma for ¥ 3.8 B

29 March 2024 | News

To proceed with transfer of the marketing capability by March 2025



Eisai Co. has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical.

Merislon and Myonal have been widely used by patients in Japan for a long time since their launch in 1969 and 1983, respectively. Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products' disease areas, is the most optimal choice to ensure them to continue contributing to a greater number of patients.

Under the terms of the agreement, Eisai will receive 3.8 billion yen (¥) for the transfer, and proceed with transfer of the marketing capability by March 2025, followed by the transfer of the manufacturing and marketing approval. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2024.